Recent Quotes
My Watchlist
Indicators
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. - ADSs (NQ:NBTX)

36.37 -1.63 (-4.30%)
Streaming Delayed Price Updated: 2:39 PM EDT, Jun 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nanobiotix S.A. - ADSs

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications
From NANOBIOTIX
Via Business Wire
News headline image
NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022
From Nanobiotix
Via Business Wire
News headline image
CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX Provides First Quarter Operational and Financial Update
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX to Participate in Two Upcoming Investor Conferences
From Nanobiotix
Via Business Wire
News headline image
7 Biotech Stocks With Key Catalysts for May ↗
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. 
Via InvestorPlace
News headline image
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022
From NANOBIOTIX
Via Business Wire
News headline image
New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting
From NANOBIOTIX
Via Business Wire
News headline image
Nanobiotix's Radiotherapy Combo Therapy Shows Boosted Anti-Tumor Activity In Preclinical Studies ↗
Nanobiotix SA (NASDAQ: NBTX)  
Via Benzinga
News headline image
NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3
From NANOBOTIX
Via Business Wire
News headline image
NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F
From NANOBIOTIX
Via Business Wire
News headline image
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results
From NANOBIOTIX
Via Business Wire
News headline image
Earnings Scheduled For March 30, 2022 ↗
Companies Reporting Before The Bell • Orgenesis (NASDAQ:ORGS) is likely to report earnings for its fourth quarter. • RumbleON (NASDAQ:RMBL) is estimated to report earnings for its Fiscal Year 2021. 
Via Benzinga
News headline image
NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022
From NANOBIOTIX
Via Business Wire
News headline image
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From NANOBIOTIX
Via Business Wire
News headline image
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer
From Nanobiotix
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Epizyme (NASDAQ:EPZM) stock increased by 14.2% to $1.41 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume of 9.6... 
Via Benzinga
News headline image
NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4
From NANOBIOTIX
Via Business Wire
News headline image
Is Oncolytics Biotech's GOBLET Study Making Headway in the Fight Against Pancreatic and Colorectal Tumors? ↗
Photo by Lucas Vasques on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.... 
Via Benzinga
News headline image
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
News headline image
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
From NANOBIOTIX
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Eargo (NASDAQ:EAR) stock increased by 50.0% to $6.84 during Thursday's regular session. The current volume of 90.4 million shares is 5474.6% of Eargo's... 
Via Benzinga
News headline image
58 Biggest Movers From Yesterday ↗
Gainers Eargo, Inc. (NASDAQ: EAR) shares climbed 59.7% to close at $7.28 on Thurs after the company announced the Department of Justice confirmed to it that the previously-... 
Via Benzinga
News headline image
NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer
From NANOBIOTIX
Via Business Wire
News headline image
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022
From Nanobiotix
Via Business Wire
News headline image
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Gift this article